Hit-To-Lead In-Depth Focus 2019
Posted: 10 December 2019 | Drug Target Review | No comments yet
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
Included in this in-depth focus:
- Hit-to-lead in neglected diseases – it’s a numbers game
The hit-to-lead journey can be a long endeavour, with many failures along the way. Nikki Withers spoke with DNDi ’s Discovery Director Dr Charles Mowbray to hear how the organisation is working to identify new leads with activity in animal models of neglected tropical diseases and the potential for further optimisation. - Transitioning novel peptide hits into lead compounds
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
